Quick Takeaways
- Caligan Partners LP filed SCHEDULE 13G for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 6.3%.
- Date of event: 30 Sep 2025.
Caligan Partners LP - 30 Sep 2025 SCHEDULE 13G Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- Caligan Partners LP
- Reporting Manager
- Caligan Partners LP
- Symbol
- AVTX
- Shares outstanding
- 13,227,508 shares
- Disclosed Ownership
- 833,333 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 14:31:46 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Caligan Partners LP disclosed 6.3% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 14:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 6.3% | 833,333 | 0 | 833,333 | /s/ David Johnson | David Johnson, Managing Partner | |
| David Johnson | 6.3% | 833,333 | 0 | 833,333 | /s/ David Johnson | David Johnson, Individually |